Various exemplary methods and devices (10, 110, 210) for delivering liquid therapeutic agents in solid tumors are provided. In general, a delivery device configured to deliver a liquid therapeutic agent into a solid tumor or other soft tissue can be configured to compress tissue and seal any fluid gaps around the delivery device during the delivery of the liquid therapeutic agent. In an exemplary embodiment the delivery device includes three elongate tubular shafts (12, 14, 16, 112, 114, 116, 212, 214, 216) configured to move longitudinally relative to one another. The elongate tubular shafts are configured to cooperate with one another to deliver the liquid therapeutic agent through a passageway of the delivery device to the solid tumor or other soft tissue and seal any fluid gaps around the delivery device while the liquid therapeutic agent is delivered into the solid tumor or other soft tissue.

A method of delivering a therapeutic agent to a nucleus pulposus of an intervertebral disc is provided. The method comprises inserting a delivery tool containing the therapeutic agent through an anterior portion, a lateral portion, or an anterolateral portion of an annulus fibrosus and into the nucleus pulposus of the intervertebral disc; and delivering the therapeutic agent to the nucleus pulposus of the intervertebral disc. Devices and kits are also provided.

A primary container assembly includes a primary container defining a body having a proximal end defining an opening configured to receive a plunger, a distal end opposite the proximal end and defining an outlet, and a chamber extending from the proximal end to the distal end that is configured to receive a drug. The primary container assembly further comprises a tube extending from a first end that is integrally attached to the distal end of the primary container to a second end opposite the first end, where the tube defines a channel extending from the first end to the second end. The primary container assembly also includes a hollow needle configured to penetrate skin of a patient.

Fluid injection device for injecting a fluid behind a tympanic membrane of a patient, comprising: a hollow needle having a needle tip with a fluid outlet at a distal end thereof, the needle tip being configured for piercing the tympanic membrane of the patient; a container for storing the fluid to be injected behind the tympanic membrane, the container being arranged in fluid communication with the hollow needle; characterised, in that the hollow needle comprises an elongated venting aperture in an outer wall thereof, the elongated venting aperture being positionable at an inner side of an ear membrane of the patient as well as at an outer ide of said ear membrane when injecting fluid, so as to allow excess fluid on the inner side of said membrane to flow through the elongated venting aperture, to the outer side of said membrane.

Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.

A method of delivering a therapeutic agent to a nucleus pulposus of an intervertebral disc is provided. The method comprises inserting a delivery tool containing the therapeutic agent through an anterior portion, a lateral portion, or an anterolateral portion of an annulus fibrosus and into the nucleus pulposus of the intervertebral disc and delivering the therapeutic agent to the nucleus pulposus of the intervertebral disc. Devices and kits are also provided.

A drug solution injection device includes: a catheter that has a hollow shaft, a hollow needle portion disposed on a distal end of the hollow shaft, and a lumen formed inside each of the hollow shaft and the needle portion and containing a drug solution; and a wire that is inserted into the lumen and is advanced from a proximal end of the lumen toward a distal end side so as to discharge the drug solution in the lumen from a distal end of the needle portion.

The present invention is directed to systems, devices and methods for trans-septally delivering carbon dioxide through a minimally invasive catheter to create a gaseous pocket or emphysema between the posterior wall of the left atrium and the esophagus during cardiac ablation of the left atrium. This pocket of gas expanded tissue serves to thermally insulate and separate the esophagus from the left atrium during ablation to prevent the formation of an atrial-esophageal fistula. The system comprises a control system to precisely deliver the gas to a desired location through a needle-based catheter assembly.

The present invention is directed to systems, devices and methods for trans-septally delivering carbon dioxide through a minimally invasive catheter to create a gaseous pocket or emphysema between the posterior wall of the left atrium and the esophagus during cardiac ablation of the left atrium. This pocket of gas expanded tissue serves to thermally insulate and separate the esophagus from the left atrium during ablation to prevent the formation of an atrial-esophageal fistula. The system comprises a control system to precisely deliver the gas to a desired location through a needle-based catheter assembly.

Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.